It depends on the insurance and the patients condition
Benefits AOD-9604 is believed to help with: Mechanistically designed to support fat breakdown and reduce new fat formation while having minimal direct impact on blood sugar and IGF1. May offer modest additional help with fat metabolism when combined with calorie control and exercise, particularly in higheradiposity individuals. Typically administered as a daily subcutaneous injection in low doses, integrated into a broader metabolic and lifestyle protocol. Longterm clinical safety data show generally good tolerability in studied populations, but regulators have highlighted unresolved immunogenicity and impurity concerns, so usage must remain cautious and fully consented. Positioned as an optional, supportive layernot a standalone weight-loss solutionwith emphasis on lab monitoring, habit coaching, and realistic expectations.
No phase 1, phase 2, or phase 3 clinical trials have been conducted
Severe injuries or post-surgical recovery may benefit from longer courses, while acute injuries might respond well to shorter intensive protocols
Raw data were analyzed on Compound Discoverer 3.2 using HMDB, KEGG, mzCloud and LipidMaps databases